Purpose.-Quality of life evaluations can enhance traditional measures
of therapeutic efficacy. The purpose of our study was to evaluate the
impact of sumatriptan on the quality of life of patients with migraine
headaches. Patients and Methods.-Migraine patients who were given a p
rescription for sumatriptan completed an SF-36 questionnaire and a nin
e-item pain questionnaire. Six to 9 months later, patients were mailed
another copy of the SF-36 and the nine-item pain questionnaire. We co
mpared the pretreatment and posttreatment scores for the SF-36 and for
each question of the nine-item pain questionnaire. Results.-The pretr
eatment SF-36 was completed by 255 patients. The pretreatment pain que
stionnaire was completed by 86 of these patients. Follow-up questionna
ires were returned by 147 patients (58%). Three of the eight SF-36 sca
les: role functioning-physical. bodily pain, and social functioning sh
owed significant (P<0.05) improvement with treatment. On the nine-item
pain-specific questionnaire, three items - pain interference with nor
mal work, ability to walk or move about, and enjoyment of life showed
statistically significant (P<0.05) improvement after sumatriptan treat
ment. Conclusions.-Sumatriptan caused a significant improvement in the
quality of life of patients with very severe migraine. This improveme
nt was measurable by both the general quality of life instrument and t
he pain-specific questionnaire.